Bank Of New York Mellon Corp Foghorn Therapeutics Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$4.66 - $8.99 $331,009 - $638,577	71,032 New	71,032 $440 Million
Q4 2022 Feb 14, 2023	BUY	$5.44 - $9.46 $386,501 - $672,114	71,048 New	71,048 $453,000
Q3 2022 Nov 14, 2022	BUY	$7.52 - $18.01 $114,710 - $274,724	15,254 Added 29.92%	66,237 $569,000
Q2 2022 Aug 15, 2022	SELL	$8.48 - $16.84 $85,902 - $170,589	-10,130 Reduced 16.58%	50,983 $693,000
Q1 2022 May 11, 2022	SELL	$8.87 - $22.1 $357,691 - $891,204	-40,326 Reduced 39.75%	61,113 $931,000
Q4 2021 Feb 11, 2022	BUY	$10.79 - $22.87 $521,383 - $1.11 Million	48,321 Added 90.97%	101,439 $2.32 Million
Q3 2021 Nov 12, 2021	BUY	$8.33 - $15.02 $14,152 - $25,518	1,699 Added 3.3%	53,118 $740,000
Q2 2021 Aug 11, 2021	BUY	$9.32 - $13.26 $298,044 - $424,041	31,979 Added 164.5%	51,419 $548,000
Q1 2021 May 13, 2021	BUY	$11.8 - $23.11 $15,977 - $31,290	1,354 Added 7.49%	19,440 $256,000
Q4 2020 Feb 09, 2021	BUY	$15.12 - $25.88 $273,460 - $468,065	18,086 New	18,086 $366,000

32.7M

1.8K

Ticker FHTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,637,400
Market Cap $336M
Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.